Workflow
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
CKPTCheckpoint Therapeutics(CKPT) Newsfilter·2024-05-15 20:15

Fortress' late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 potential BLA resubmission, which is currently targeted for mid-year. Cosibelimab is currently in development at our partner company, Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) ("Checkpoint"). Based on its public statements, AstraZeneca plc has estimated that it expects the FDA to accept its BLA submission of CAEL-10 ...